Robert Moramarco, OTR in Rochester, VT - Occupational Therapist

Robert Moramarco, OTR is a Occupational Therapist based in Rochester, Vermont. Robert Moramarco is licensed to practice in Vermont (license number 072-0000494) and his current practice location is 77 Kennedy Dr, Rochester, Vermont. He can be reached at his office (for appointments etc.) via phone at (802) 767-4230.

NPI number for Robert Moramarco is 1043331580 and his current mailing address is 77 Kennedy Dr, Rochester, Vermont. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1043331580.

Contact Information

	Robert Moramarco, OTR
	77 Kennedy Dr, Rochester, VT 05767-9694
	(802) 767-4230
	Not Available

Healthcare Provider's Profile

Full Name	Robert Moramarco
Gender	Male
Speciality	Occupational Therapist
Location	77 Kennedy Dr, Rochester, Vermont
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1043331580
Provider Enumeration Date: 04/03/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Robert Moramarco such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1043331580	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
225X00000X	Occupational Therapist	072-0000494 (Vermont)	Primary
225X00000X	Occupational Therapist	3845 (Massachusetts)	Secondary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Robert Moramarco is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Robert Moramarco, OTR 77 Kennedy Dr, Rochester, VT 05767-9694 Ph: (802) 767-4230	Robert Moramarco, OTR 77 Kennedy Dr, Rochester, VT 05767-9694 Ph: (802) 767-4230

News Archive

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.

University of Utah students develop new, 100% biodegradable feminine maxi pad

Each year, nearly 20 billion sanitary pads, tampons and applicators are dumped into North American landfills every year, and it takes centuries for them to biodegrade inside plastic bags, according to a 2016 Harvard Business School report. Additionally, it requires high amounts of fossil fuel energy to produce the plastic for these products, resulting in a large carbon footprint.

FDA approves new chewable formulation of Zyrtec® aimed at young allergy sufferers

Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.

CSHL scientists solve the mystery of why some infants born with grave syndrome

By identifying a protein that acts as a genetic modifier, scientists at Cold Spring Harbor Laboratory have solved the mystery of why some infants are born with a grave syndrome consisting of cleft palate and major deformities of the skin and limbs, while other infants bearing the same predisposing genetic mutation bear little or no sign of the illness, called EEC.

Robert Moramarco, OTR - Occupational Therapist in Rochester, VT